Anne Petzold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Petzold has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Carola Berking
Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
7 shared publications - Markus Valentin Heppt
Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
7 shared publications - Anja Wessely
Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
6 shared publications - Elias A. T. Koch
Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
5 shared publications - Theresa Steeb
Department of Dermatology, University Hospital Erlangen, 91054 Erlangen, Germany
3 shared publications - Anja Gesierich
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
2 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-12
Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology
Psoriasis and eczema are chronic inflammatory skin diseases with overlapping histopathological features, which often lead to diagnostic uncertainty even among experienced dermatopathologists. To address this challenge, we developed a computer-assisted diagnostic framework that combines the Virchow foundation model, pretrained on 1.5 million whole-slide images, with multi-instance learning (MIL) to classify psoriasis and eczema from digitized histopathology slides. Using an internal dataset ( n = 40) and an external validation cohort ( n = 40), equally balanced between both conditions and annotated by board-certified dermatopathologists, our best-performing configuration (Virchow + CLAM) achieved 85% accuracy, a macro-averaged F1 score of 0.80, and an AUC of 0.81 on the external cohort. This substantially outperformed baseline convolutional neural networks, which reached 61% accuracy, and models relying solely on pretrained feature extractors without MIL, which achieved an average accuracy of 68.8%. In a reader study on the same external cohort, individual dermatopathologist accuracies ranged from 47.5 to 70.0%, with a majority-vote consensus accuracy of 62.5%; our method outperformed both the average individual reader and the consensus under histology-only conditions. Furthermore, the model generates attention heatmaps that provide supportive visual context by highlighting regions associated with model predictions. Importantly, this study is designed as a methodological proof-of-concept conducted under controlled, histology-only conditions and is not intended for direct clinical deployment. Rather than demonstrating clinical readiness, it illustrates the potential of domain-specific foundation models combined with MIL for addressing diagnostically challenging inflammatory dermatoses.
- 20 February 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-12
Open AccessVision transformer-based diagnosis of psoriasis and eczema in whole-slide histology
Psoriasis and eczema are chronic inflammatory skin diseases with overlapping histopathological features, which often lead to diagnostic uncertainty even among experienced dermatopathologists. To address this challenge, we developed a computer-assisted diagnostic framework that combines the Virchow foundation model, pretrained on 1.5 million whole-slide images, with multi-instance learning (MIL) to classify psoriasis and eczema from digitized histopathology slides. Using an internal dataset ( n = 40) and an external validation cohort ( n = 40), equally balanced between both conditions and annotated by board-certified dermatopathologists, our best-performing configuration (Virchow + CLAM) achieved 85% accuracy, a macro-averaged F1 score of 0.80, and an AUC of 0.81 on the external cohort. This substantially outperformed baseline convolutional neural networks, which reached 61% accuracy, and models relying solely on pretrained feature extractors without MIL, which achieved an average accuracy of 68.8%. In a reader study on the same external cohort, individual dermatopathologist accuracies ranged from 47.5 to 70.0%, with a majority-vote consensus accuracy of 62.5%; our method outperformed both the average individual reader and the consensus under histology-only conditions. Furthermore, the model generates attention heatmaps that provide supportive visual context by highlighting regions associated with model predictions. Importantly, this study is designed as a methodological proof-of-concept conducted under controlled, histology-only conditions and is not intended for direct clinical deployment. Rather than demonstrating clinical readiness, it illustrates the potential of domain-specific foundation models combined with MIL for addressing diagnostically challenging inflammatory dermatoses.
- Open Access
- 25 September 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 1047-1058
An artificial intelligence model of whole-slide pathology specimens differentiating cutaneous high-grade squamous proliferations
Cutaneous squamous cell carcinoma (cSCC) and verruca vulgaris (VV) are skin conditions involving the proliferation of epidermal keratinocytes requiring fundamentally different treatments. Histological evaluation of highly differentiated squamous cell proliferations can be challenging, particularly in small or superficial samples. This study aims to improve diagnostic accuracy using an AI model to distinguish cSCC from VV. We developed a deep-learning model using clustering-constrained attention multiple instance learning (CLAM) to classify hematoxylin and eosin-stained whole-slide images (WSIs) as cSCC or VV. The dataset comprised 289 WSIs (n = 148 cSCC, n = 141 VV). Quality control was ensured through expert review: the training cohort was evaluated by four dermatopathologists, and the evaluation cohort by six additional experts. On the training set, the model achieved an AUROC of 0.99, with an accuracy of 94.9% for cSCC and 91.2% for VV. On the evaluation set, it reached an AUROC of 0.96, and accuracies of 82.4% (cSCC) and 97.4% (VV), similar to the average performance of individual dermatopathologists. We successfully trained and implemented an interpretable deep-learning-based weakly supervised model on WSIs distinguishing cSCC from VV, which could enhance AI-supported diagnostics in the future.
- 25 September 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 1047-1058
Open AccessAn artificial intelligence model of whole-slide pathology specimens differentiating cutaneous high-grade squamous proliferations
Cutaneous squamous cell carcinoma (cSCC) and verruca vulgaris (VV) are skin conditions involving the proliferation of epidermal keratinocytes requiring fundamentally different treatments. Histological evaluation of highly differentiated squamous cell proliferations can be challenging, particularly in small or superficial samples. This study aims to improve diagnostic accuracy using an AI model to distinguish cSCC from VV. We developed a deep-learning model using clustering-constrained attention multiple instance learning (CLAM) to classify hematoxylin and eosin-stained whole-slide images (WSIs) as cSCC or VV. The dataset comprised 289 WSIs (n = 148 cSCC, n = 141 VV). Quality control was ensured through expert review: the training cohort was evaluated by four dermatopathologists, and the evaluation cohort by six additional experts. On the training set, the model achieved an AUROC of 0.99, with an accuracy of 94.9% for cSCC and 91.2% for VV. On the evaluation set, it reached an AUROC of 0.96, and accuracies of 82.4% (cSCC) and 97.4% (VV), similar to the average performance of individual dermatopathologists. We successfully trained and implemented an interpretable deep-learning-based weakly supervised model on WSIs distinguishing cSCC from VV, which could enhance AI-supported diagnostics in the future.
- Open Access
- 4 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1896
Actinic Cheilitis: A Systematic Review and Meta-Analysis of Interventions, Treatment Outcomes, and Adverse Events
Introduction: Actinic cheilitis (AC) is a common precancerous condition affecting the lips, primarily caused by prolonged ultraviolet radiation exposure. Various treatment options are available. However, the optimal treatment approach remains a subject of debate. Objective: To summarize and compare practice-relevant interventions for AC. Materials and Methods: A pre-defined protocol was registered in PROSPERO (CRD42021225182). Systematic searches in Medline, Embase, and Central, along with manual trial register searches, identified studies reporting participant clearance rates (PCR) or recurrence rates (PRR). Quality assessment for randomized controlled trials (RCTs) was conducted using the Cochrane Risk of Bias tool 2. Uncontrolled studies were evaluated using the tool developed by the National Heart, Lung, and Blood Institute. The generalized linear mixed model was used to pool proportions for uncontrolled studies. A pairwise meta-analysis for RCTs was applied, using the odds ratio (OR) as the effect estimate and the GRADE approach to evaluate the quality of the evidence. Adverse events were analyzed qualitatively. Results: A comprehensive inclusion of 36 studies facilitated an evaluation of 614 participants for PCR, and 430 patients for PRR. Diclofenac showed the lowest PCR (0.53, 95% confidence interval (CI) [0.41; 0.66]), while CO2 laser showed the highest PCR (0.97, 95% CI [0.90; 0.99]). For PRR, Er:YAG laser showed the highest rates (0.14, 95% CI [0.08; 0.21]), and imiquimod the lowest (0.00, 95% CI [0.00; 0.06]). In a pairwise meta-analysis, the OR indicated a lower recurrence rate for Er:YAG ablative fractional laser (AFL)-primed methyl-aminolevulinate photodynamic therapy (MAL-PDT) (Er:YAG AFL-PDT) compared to methyl-aminolevulinate photodynamic therapy (MAL-PDT) alone (OR = 0.22, 95% CI [0.06; 0.82]). The CO2 laser showed fewer local side effects than the Er:YAG laser, while PDTs caused more skin reactions. Due to qualitative data, comparability was limited, highlighting the need for individualized treatment. Conclusions: This study provides a complete and up-to-date evidence synthesis of practice-relevant interventions for AC, identifying the CO2 laser as the most effective treatment and regarding PCR and imiquimod as most effective concerning PRR.
- 4 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1896
Open AccessActinic Cheilitis: A Systematic Review and Meta-Analysis of Interventions, Treatment Outcomes, and Adverse Events
Introduction: Actinic cheilitis (AC) is a common precancerous condition affecting the lips, primarily caused by prolonged ultraviolet radiation exposure. Various treatment options are available. However, the optimal treatment approach remains a subject of debate. Objective: To summarize and compare practice-relevant interventions for AC. Materials and Methods: A pre-defined protocol was registered in PROSPERO (CRD42021225182). Systematic searches in Medline, Embase, and Central, along with manual trial register searches, identified studies reporting participant clearance rates (PCR) or recurrence rates (PRR). Quality assessment for randomized controlled trials (RCTs) was conducted using the Cochrane Risk of Bias tool 2. Uncontrolled studies were evaluated using the tool developed by the National Heart, Lung, and Blood Institute. The generalized linear mixed model was used to pool proportions for uncontrolled studies. A pairwise meta-analysis for RCTs was applied, using the odds ratio (OR) as the effect estimate and the GRADE approach to evaluate the quality of the evidence. Adverse events were analyzed qualitatively. Results: A comprehensive inclusion of 36 studies facilitated an evaluation of 614 participants for PCR, and 430 patients for PRR. Diclofenac showed the lowest PCR (0.53, 95% confidence interval (CI) [0.41; 0.66]), while CO2 laser showed the highest PCR (0.97, 95% CI [0.90; 0.99]). For PRR, Er:YAG laser showed the highest rates (0.14, 95% CI [0.08; 0.21]), and imiquimod the lowest (0.00, 95% CI [0.00; 0.06]). In a pairwise meta-analysis, the OR indicated a lower recurrence rate for Er:YAG ablative fractional laser (AFL)-primed methyl-aminolevulinate photodynamic therapy (MAL-PDT) (Er:YAG AFL-PDT) compared to methyl-aminolevulinate photodynamic therapy (MAL-PDT) alone (OR = 0.22, 95% CI [0.06; 0.82]). The CO2 laser showed fewer local side effects than the Er:YAG laser, while PDTs caused more skin reactions. Due to qualitative data, comparability was limited, highlighting the need for individualized treatment. Conclusions: This study provides a complete and up-to-date evidence synthesis of practice-relevant interventions for AC, identifying the CO2 laser as the most effective treatment and regarding PCR and imiquimod as most effective concerning PRR.
- Open Access
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
Open AccessImmune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
- Open Access
- 15 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4736
How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results
Actinic keratoses (AK) are common lesions of the skin caused by cumulative sun exposure. Since AK may progress to invasive cutaneous squamous cell carcinoma (cSCC), guidelines uniformly recommend early and consequent treatment. A variety of interventions are available; however, most randomized controlled trials, meta-analyses, and guidelines focus on outcomes that are usually evaluated 8–12 weeks after the end of treatment. Importantly, these assessments can capture the short-term, transient outcomes, but do not allow any conclusions about long-term results to be drawn and do not reflect the probability of transition towards cSCC. Until now, few studies have assessed the long-term results of interventions for AK. Indeed, finding the most appropriate end-point and adjunct time point for determining the long-term results of interventions for AK remains a challenge. Here, we provide an overview of the different ways of measuring the efficacy of AK treatments, such as using recurrence rates or sustained clearance rates, and discuss methodological aspects. Furthermore, we highlight the importance of evidence from post-marketing surveillance trials for the detection of efficacy values and safety signals. Additionally, we emphasize that a follow-up period of 12 months might not be sufficient to reflect the long-term results and stress the urgent need for a longer follow-up period and regular risk-stratified surveillance.
- 15 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (20) , 4736
Open AccessHow to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results
Actinic keratoses (AK) are common lesions of the skin caused by cumulative sun exposure. Since AK may progress to invasive cutaneous squamous cell carcinoma (cSCC), guidelines uniformly recommend early and consequent treatment. A variety of interventions are available; however, most randomized controlled trials, meta-analyses, and guidelines focus on outcomes that are usually evaluated 8–12 weeks after the end of treatment. Importantly, these assessments can capture the short-term, transient outcomes, but do not allow any conclusions about long-term results to be drawn and do not reflect the probability of transition towards cSCC. Until now, few studies have assessed the long-term results of interventions for AK. Indeed, finding the most appropriate end-point and adjunct time point for determining the long-term results of interventions for AK remains a challenge. Here, we provide an overview of the different ways of measuring the efficacy of AK treatments, such as using recurrence rates or sustained clearance rates, and discuss methodological aspects. Furthermore, we highlight the importance of evidence from post-marketing surveillance trials for the detection of efficacy values and safety signals. Additionally, we emphasize that a follow-up period of 12 months might not be sufficient to reflect the long-term results and stress the urgent need for a longer follow-up period and regular risk-stratified surveillance.
- Open Access
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Open AccessImmune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.